Long-term prognostic implications and therapeutic target role of hexokinase II in patients with nasopharyngeal carcinoma

Oncotarget

Volumn 7, Issue 16, 2016, Pages 21287-21297

  Zhang, Meng Xia ^a   Hua, Yi Jun ^a   Wang, Hai Yun ^a   Zhou, Ling ^a   Mai, Hai Qiang ^a   Guo, Xiang ^a   Zhao, Chong ^a   Huang, Wen Lin ^a   Hong, Ming Huang ^a   Chen, Ming Yuan ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

3 bromo 2 oxopropionate 1 propyl ester (3 BrOP); Hexokinase II (HK II); Nasopharyngeal carcinoma (NPC); Survival; Therapeutic target

Indexed keywords

3 BROMO 2 OXOPROPIONATE 1 PROPYL ESTER; ADENOSINE TRIPHOSPHATE; CISPLATIN; HEXOKINASE; HEXOKINASE II; PHOSPHOTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; 3-BROMO-2-OXOPROPIONATE-1-PROPYL ESTER; BROMINATED HYDROCARBON; PROPIONIC ACID DERIVATIVE; TUMOR MARKER;

ADULT; AGED; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CANCER PROGNOSIS; CELL HYPOXIA; CELL INVASION; CONTROLLED STUDY; DISTANT METASTASIS FREE SURVIVAL; DRUG POTENTIATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; ANTAGONISTS AND INHIBITORS; CARCINOMA; CELL CYCLE; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; MIDDLE AGED; NASOPHARYNX TUMOR; OXIDATIVE PHOSPHORYLATION; PATHOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR CELL CULTURE; YOUNG ADULT;

ADULT; AGED; APOPTOSIS; BIOMARKERS, TUMOR; CARCINOMA; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; HEXOKINASE; HUMANS; HYDROCARBONS, BROMINATED; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; OXIDATIVE PHOSPHORYLATION; PROGNOSIS; PROPIONATES; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 84965044077     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7116     Document Type: Article

References (29)

1. Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet. 2005; 365:2041-2054.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011; 61:69-90.
3. Cao SM, Simons MJ, Qian CN. The prevalence and prevention of nasopharyngeal carcinoma in China. Chinese journal of cancer. 2011; 30:114-119.
4. Lai SZ, Li WF, Chen L, Luo W, Chen YY, Liu LZ, Sun Y, Lin AH, Liu MZ, Ma J. How does intensitymodulated radiotherapy versus conventional twodimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? International journal of radiation oncology, biology, physics. 2011; 80:661-668.
5. Yu KH, Leung SF, Tung SY, Zee B, Chua DT, Sze WM, Law SC, Kam MK, Leung TW, Sham JS, Lee AW, Au JS, Hui EP, et al. Survival outcome of patients with nasopharyngeal carcinoma with first local failure: a study by the Hong Kong Nasopharyngeal Carcinoma Study Group. Head & neck. 2005; 27:397-405.
6. Li AC, Xiao WW, Shen GZ, Wang L, Xu AA, Cao YQ, Huang SM, Lin CG, Han F, Deng XW, Zhao C. Distant metastasis risk and patterns of nasopharyngeal carcinoma in the era of IMRT: long-term results and benefits of chemotherapy. Oncotarget. 2015; 6:24511-24521. doi: 10.18632/oncotarget.4312
7. Lee N, Harris J, Garden AS, Straube W, Glisson B, Xia P, Bosch W, Morrison WH, Quivey J, Thorstad W, Jones C, Ang KK. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009; 27:3684-3690.
8. Sotgia F, Martinez-Outschoorn UE, Lisanti MP. Cancer metabolism: new validated targets for drug discovery. Oncotarget. 2013; 4:1309-1316. doi: 10.18632/oncotarget.1182.
9. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene. 2006; 25:4633-4646.
10. Seyfried TN, Shelton LM. Cancer as a metabolic disease. Nutrition & metabolism. 2010; 7:7.
11. Kaelin WG, Jr., Thompson CB. Q & A: Cancer: clues from cell metabolism. Nature. 2010; 465:562-564.
12. Tsukada H, Muramatsu T, Miyazawa M, Iida T, Ikeda M, Shida M, Hirasawa T, Kajiwara H, Murakami M, Yasuda M, Mikami M. Long Term Prognostic Implications of Expression of Glucose Transporter-1 and Hexokinase II in Patients with Stage I Uterine Leiomyosarcoma. Acta histochemica et cytochemica. 2012; 45:147-154.
13. Mamede M, Higashi T, Kitaichi M, Ishizu K, Ishimori T, Nakamoto Y, Yanagihara K, Li M, Tanaka F, Wada H, Manabe T, Saga T. [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia. 2005; 7:369-379.
14. Paudyal B, Oriuchi N, Paudyal P, Higuchi T, Nakajima T, Endo K. Expression of glucose transporters and hexokinase II in cholangiocellular carcinoma compared using [18F]-2-fluro-2-deoxy-D-glucose positron emission tomography. Cancer science. 2008; 99:260-266.
15. Xu RH, Pelicano H, Zhang H, Giles FJ, Keating MJ, Huang P. Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells. Leukemia. 2005; 19:2153-2158.
16. Chen Z, Lu W, Garcia-Prieto C, Huang P. The Warburg effect and its cancer therapeutic implications. Journal of bioenergetics and biomembranes. 2007; 39:267-274.
17. Akers LJ, Fang W, Levy AG, Franklin AR, Huang P, Zweidler-McKay PA. Targeting glycolysis in leukemia: a novel inhibitor 3-BrOP in combination with rapamycin. Leukemia research. 2011; 35:814-820.
18. Wangpaichitr M, Savaraj N, Maher J, Kurtoglu M, Lampidis TJ. Intrinsically lower AKT, mammalian target of rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy-D-glucose under hypoxia in lung cancer cell lines. Molecular cancer therapeutics. 2008; 7:1506-1513.
19. Jin ZJ. About the evaluation of drug combination. Acta pharmacologica Sinica. 2004; 25:146-147.
20. Hajra KM, Liu JR. Apoptosome dysfunction in human cancer. Apoptosis: an international journal on programmed cell death. 2004; 9:691-704.
21. Warburg O. On the origin of cancer cells. Science. 1956; 123:309-314.
22. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324:1029-1033.
23. Aubert JP. [The Pasteur effect]. L' Annee biologique. 1951; 55:197-212.
24. Bustamante E, Morris HP, Pedersen PL. Energy metabolism of tumor cells. Requirement for a form of hexokinase with a propensity for mitochondrial binding. The Journal of biological chemistry. 1981; 256:8699-8704.
25. Chen Z, Zhang H, Lu W, Huang P. Role of mitochondriaassociated hexokinase II in cancer cell death induced by 3-bromopyruvate. Biochimica et biophysica acta. 2009; 1787:553-560.
26. Pedersen PL, Mathupala S, Rempel A, Geschwind JF, Ko YH. Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochimica et biophysica acta. 2002; 1555:14-20.
27. Szablewski L. Expression of glucose transporters in cancers. Biochimica et biophysica acta. 2013; 1835:164-169.
28. Levy AG, Zage PE, Akers LJ, Ghisoli ML, Chen Z, Fang W, Kannan S, Graham T, Zeng L, Franklin AR, Huang P, Zweidler-McKay PA. The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastoma. Investigational new drugs. 2012; 30:191-199.
29. Konno R, Yamakawa H, Utsunomiya H, Ito K, Sato S, Yajima A. Expression of survivin and Bcl-2 in the normal human endometrium. Molecular human reproduction. 2000; 6:529-534.